MLTX 8-K 2026-11-04
MoonLake Immunotherapeutics (MLTX) 8-K dated 2026-11-04 — accession 0001821586-26-000013.
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on US.
MLTX: MoonLake Reports Third Quarter 2026 Financial Results and Provides a Bu…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Income-statement cache for MLTX is thin on this filing URL. We will not invent exhibit numbers.
Not investment advice. The MLTX SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its
Why it matters
- expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its